Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia
Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy, safety, and pharmacokinetics of AGN-190584 when
administered bilaterally, once daily for 30 days in participants with presbyopia.